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Cancer provides a foreign antigen
Temporal clustering of the autoimmune rheumatic disease 
scleroderma and cancer has been observed, but only sclero-
derma patients harboring autoantibodies to RNA polymerase III 
(RPC1)—not patients with autoantibodies to topoisomerase 1 or 
centromere protein B—exhibit this association, suggesting that 
these diseases may be linked mechanistically. Joseph and col-
leagues recently uncovered missense mutations or loss of het-
erozygosity at the RPC1 (POLR3A) locus in six of eight cancers 
from patients with antibodies to RPC1. Patients with antibodies 
to the other target autoantigens did not harbor these mutations. 
The investigators also identified autoreactive T cells specific to 
mutant RPC1 in the peripheral blood of two of these patients. 
Together, these findings suggest that POLR3A mutations may ini-
tiate an immune response to RPC1 in a subset of scleroderma 
patients. Thus, the foreign antigen that elicits the autoimmune 
response in scleroderma patients may be a tumor antigen. 
(Science 343:152–7, 2014) Selected by T. Schwarz
Too much information?
With an increase in availability and a decrease in cost, whole-
genome sequencing (WGS) is being applied more frequently 
in the setting of clinical medicine. Although this technique is 
expected to yield clinically significant findings, the burden of 
clinically reportable inherited disease risk and pharmacoge-
nomics findings, the resources needed for interpretation of 
these findings, and the cost of the resultant clinical follow-up 
remain unknown, yet critical, entities. Recently, Dewey and 
colleagues reported the examination of WGS data from 12 
participants who exhibited no inherited disease at the time of 
sequencing. The use of WGS was linked to incomplete cover-
age of inherited disease genes (10–19% were not adequately 
covered), low reproducibility of genetic variation, and uncer-
tainty about clinically reportable data following a lengthy time 
of curation for each participant. Nonetheless, this method will 
certainly identify clinically relevant disease variants warrant-
ing medical intervention in some patients. (JAMA 311:1035–
44, 2014) Selected by J. Uitto
Of mice and men
The severe autosomal recessive skin disorder Netherton syn-
drome (NS) results in both cutaneous and immunological 
abnormalities. Because mutations in the multidomain protease 
inhibitor lymphoepithelial Kazal-type inhibitor (LEKTI), which 
is encoded by SPINK5, underlie NS, previous work to delete 
Spink5 in mice resulted in animals that recapitulate NS fea-
tures but die shortly after birth, yielding a confirmatory model 
that does not allow further examination of patho physiology 
or potential treatment options. Thus, Furio and colleagues 
generated mice that overexpress kallikrein-related peptidase 
(KLK) 5, a protease that is known to be inhibited by LEKTI and 
that, in the absence of LEKTI in NS, remains unchecked in the 
skin. These mice exhibited characteristic hallmarks of NS, 
including exfoliative erythroderma, scaling, growth delay, hair 
abnormalities, defective skin barrier, detached stratum cor-
neum, and cutaneous signs of allergy and inflammation. These 
findings confirm the role of KLK5 in NS and provide a novel 
mouse model for further investigation of NS and preclinical test-
ing of potential therapies for NS or the related disease, atopic 
dermatitis. (J Exp Med 211:499–513, 2014) Selected by N. Ward
Double trouble
Although mutations in the COL7A1 gene, which encodes col-
lagen VII, cause recessive dystrophic epidermolysis bullosa 
(RDEB) and the levels of collagen VII expression are often asso-
ciated with disease severity, the same genetic variant can actual-
ly result in highly variable clinical phenotypes, even in siblings. 
To identify molecules that mediate the varied clinical outcomes, 
Odorisio and colleagues examined monozygotic twins with 
RDEB with significant phenotypic variation despite similar col-
lagen VII abundance. Gene expression profiling of fibroblasts 
revealed that genes involved in the transforming growth factor-β 
(TGF-β) pathway were differentially expressed, highlighting a 
role for this factor in modulating disease severity. Fibroblasts 
from the more affected twin exhibited a profibrotic and proin-
flammatory phenotype as well as upregulated expression and 
constitutive activation of TGF-β. Interestingly, decorin, which 
has antifibrotic activity, was upregulated in the less affected 
twin, suggesting that this protein mitigates the disease despite 
the collagen VII levels and providing an impetus for exploration 
of decorin as a therapeutic target. (Hum Mol Genet 23:3907–
22, 2014) Selected by B. Gilchrest
The intricacies of itch
Although pruritus is a common symptom of many dermatolog-
ic, allergic, and autoimmune diseases, its neuronal regulatory 
circuits and signaling pathways are not well understood. Recent 
advances have shown that endothelin 1 (ET-1) induces itch in 
a histamine-independent manner and mediates this effect via 
endothelin A receptor (ETAR). Kido-Nakahara and colleagues 
recently demonstrated that the intracellular neural peptidase 
endothelin-converting enzyme (ECE-1) regulates ET-1-induced 
pruritus and intracellular signaling in dorsal root ganglion neu-
rons, heralding ECE-1 as the first identified endogenous negative 
regulator of itch signaling in sensory nerves. In mice, ECE-1 inhi-
bition enhanced ET-1-induced scratching, whereas treatment 
with an ERK1/2 inhibitor abrogated such behavior. In patients 
with chronic itch, the investigators found that expression of 
these components (ET-1, ETAR, ECE-1, and ERK1/2) was upregu-
lated, implicating this signaling axis as a therapeutic target for 
pruritus and other pruritic diseases in humans. (J Clin Invest 
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